Oral oncology最新文献

Commentary on, “Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department” 对“头颈癌患者急诊诊断延迟的影响”的评论

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107532

Gnanaprakash Jeyaraj

引用次数: 0

Comment on “Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer” 对“hpv相关头颈癌循环肿瘤DNA和循环细胞改变现状”的评论

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107526

Jatinder Pal Singh Chawla , Gundeep Kaur Madan

引用次数: 0

Toward comprehensive optimization of larynx-preserving strategies in MI-LSCC 对MI-LSCC保喉策略的综合优化

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107514

Rong Sun , Deqi Kong

引用次数: 0

What does margin mean in laryngeal surgery? 喉部手术的边缘是什么意思？

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107523

Oreste Gallo, Letizia Flammia

引用次数: 0

Comment on: Neoadjuvant chemoradiation for patients with resectable locally advanced oral cavity squamous cell carcinoma: Results of the prospective INVERT clinical trial 评论：可切除局部晚期口腔鳞状细胞癌患者的新辅助放化疗：前瞻性INVERT临床试验的结果

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107450

Deping Li , Yibin Wang

引用次数: 0

Story of the Tongue! 舌头的故事！

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107519

Dona Sherief, Sumyya Jaigirdar, Shadaab Mumtaz, Hassan Taqvi

引用次数: 0

Comments on, “Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan” 对“下颌摆动入路：米兰国立肿瘤研究所25年经验”的评论

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107529

Aravinth Annamalai

引用次数: 0

Turning tumor microenvironmental foes to friends: A new opportunity for thyroid cancer therapy and redifferentiation 将肿瘤微环境敌人转化为朋友：甲状腺癌治疗和再分化的新机遇

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107513

Liya Zhu , Xiuli Jing , Byeong-Cheol Ahn

{"title":"Turning tumor microenvironmental foes to friends: A new opportunity for thyroid cancer therapy and redifferentiation","authors":"Liya Zhu , Xiuli Jing , Byeong-Cheol Ahn","doi":"10.1016/j.oraloncology.2025.107513","DOIUrl":"10.1016/j.oraloncology.2025.107513","url":null,"abstract":"<div><div>Cancer cells engage in dynamic crosstalk with their microenvironment (TME), critically influencing tumor progression, metastasis, immune evasion, and therapeutic resistance. Thyroid cancer (TC) exhibits characteristic tumor heterogeneity, together with secreted factors (cytokines, chemokines, extracellular vesicles) and the extracellular matrix, these elements constitute the TME. In addition, TC-TME interactions drive key pathological processes including differentiation status across histological subtypes—from differentiated (DTC) to aggressive variants(poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC)). A hallmark of malignancy, metabolic reprogramming not only fuels uncontrolled proliferation but also actively remodels the TME through mechanisms including immune modulation, angiogenesis regulation, and stromal reprogramming. At the same time, immunotherapy represents a promising therapeutic frontier for treatment-refractory cases such as radioiodine-resistant DTC (RR-DTC), PDTC, and ATC. Emerging evidence reveals distinct mutational signatures that correlate with TME remodeling, suggesting potential diagnostic and prognostic biomarkers. While current redifferentiation approaches primarily target cancer cells with limited success, novel strategies focusing on TME modulation—particularly targeting tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and tumor-associated mast cells (TAMCs)—show therapeutic potential. Deciphering these intricate metabolic adaptations and their bidirectional interactions with the TME represents a pivotal opportunity for developing precision therapies and enhancing treatment efficacy in the clinical oncology of TC. This review synthesizes current knowledge on TME-directed therapies in TC and highlights the urgent need to elucidate metabolic reprogramming and other factors within the TME to develop innovative treatment paradigms targeting both cancer cells and TC-associated immune cells.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"168 ","pages":"Article 107513"},"PeriodicalIF":4.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Illustrating potential actionable drug targets of head and neck tumors based on comprehensive genomic landscape of 386 samples 基于386个样本的全面基因组图谱阐明头颈部肿瘤潜在的可操作药物靶点

IF 4 2区医学

Oral oncology Pub Date : 2025-07-22 DOI: 10.1016/j.oraloncology.2025.107515

Yu Lin , Luyao Liu , Dong Shen , Ling Zhang , Qin Zhang , Xuewen Liu , Dongsheng Chen , Yiqian Liu , Yongqian Shu

引用次数: 0

Comment on “Clinical outcomes for unresectable anaplastic thyroid cancer treated with radiation: Impacts of radiation intent and the percentage of life spent receiving treatment” 《放疗治疗不可切除间变性甲状腺癌的临床结果：放疗意图和接受治疗的生命百分比的影响》评论

IF 4 2区医学

Oral oncology Pub Date : 2025-07-21 DOI: 10.1016/j.oraloncology.2025.107525

Shashank Dokania, Parth Aphale, Himanshu Shekhar

引用次数: 0